InflaRx N.V. (IFRX)
| Previous Close | 1.2650 |
| Open | 1.2600 |
| Bid | 0.9864 x 200 |
| Ask | 1.6700 x 200 |
| Day's Range | 1.2500 - 1.4150 |
| 52 Week Range | 1.1400 - 5.2000 |
| Volume | |
| Avg. Volume | 229,148 |
| Market Cap | 80.081M |
| Beta (5Y Monthly) | 1.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8300 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.91 |
ZacksInflaRx N.V. (IFRX) Reports Q4 Loss, Misses Revenue Estimates
InflaRx (IFRX) delivered earnings and revenue surprises of -50% and 99.87%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireInflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
InflaRx will focus development activities and resources initially on selected indications in immuno-dermatology, with registrational-phase vilobelimab and potentially best-in-class oral C5aR inhibitor INF904 INF904 development will be initially targeted at chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), with initiation of a Phase IIa PK dose-ranging study expected by the end of 2024, with data availability anticipated in 2025 InflaRx is considering partnership options for
- GlobeNewswire
InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
JENA, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will host a conference call this Thursday, March 21, 2024 at 8:00 am ET / 1:00 pm CET to discuss the Company’s anticipated development plans for INF904, InflaRx’s orally available C5aR inhibitor with best-in-class potential. The Company will also publish its financial and operating results
